During the COVID-19 pandemic, the U.S. experienced significant blood product shortages. In 2019, approximately 2.5 million platelet units were collected in the U.S., and over 90% were collected by apheresis. Platelets may also be derived from whole blood, but these must be pooled with three to nine other whole blood derived (WBD) platelet units to make a sufficient “dose.” To explore the current opinions and preferences of blood centers with respect to WBD and apheresis platelets, the America’s Blood Centers sent an online survey to all 47 medical directors of their blood collection centers. Responses were received from 94% (44/47) of centers. While 35% (15/43) of centers reported that they are currently collecting WBD platelets and 70% of respondents agreed that WBD and apheresis platelets are clinically equivalent, 49% (21/43) indicated they are not considering collecting WBD platelets to alleviate platelet shortages. Centers reported logistical and inventory management and bacterial mitigation as the main barriers to WBD platelet collection followed by inadequate staffing and cost. Further input, discussions, and research on new technology to ease logistical and inventory hurdles are needed to ensure a safe and reliable blood supply.
Reference:
